Almanac A1C

Dyslipidemia Unmasked: A Functional Medicine Approach to Identifying and Reversing Its True Root Causes

Posted

by

A1C Medical Writer 2

Table of Contents
Keywords: , , , , , , , , , , , , , ,

Definition of Dyslipidemia

Dyslipidemia is a metabolic disorder characterized by abnormal levels of lipids in the blood stream, including cholesterol, triglycerides, phospholipids, and lipoproteins. Traditionally, clinical focus on dyslipidemia has emphasized cholesterol especially total cholesterol and low-density lipoprotein cholesterol (LDL-C)-but contemporary research reveals that understanding dyslipidemia requires a much broader perspective [1-5].

Dyslipidemia is not solely a condition of raised or lowered cholesterol. It also involves:

  • Lipoprotein Particle Size: Small, dense LDL particles have greater atherogenic potential than larger, buoyant ones. Residual dyslipidemia can include high levels of small dense LDL or small dense HDL particles, which are associated with increased cardiovascular risk even when standard cholesterol measures appear normal [3].
  • Inflammation: Abnormal lipid profiles can promote inflammation in blood vessels. The accumulation of cholesterol-rich lipoprotein remnants and foam cell formation in arterial walls triggers vascular inflammation, further elevating the risk of atherosclerosis and cardiovascular disease [4].
  • Metabolic Dysfunction: Dyslipidemia often coexists with metabolic syndrome, diabetes, and obesity- conditions defined by systemic metabolic disturbances. These conditions contribute to patterns such as high triglycerides, low HDL, and altered lipoprotein functionality, independent of cholesterol values alone [3,4,6].

Diagnosis requires advanced lipid and lipoprotein profiling, as many deleterious changes are not captured by routine cholesterol testing. Elevated triglycerides, low HDL cholesterol, increased Lipoprotein(a) [Lp(a)], and the predominance of small, dense lipoprotein particles may contribute to risk even when LDL-C is controlled [1,3,4].

By considering these broader aspects- particle size, inflammatory status, and metabolic dysfunction- the definition of dyslipidemia more accurately reflects its multi-factorial role in cardiovascular disease and metabolic health.

Keywords: Dyslipidemia , LDL, particle size, Lp(a), triglycerides, HDL, LDL

Functional Medicine Lens

Root Causes of Dyslipidemia from a Functional Medicine Perspective

From functional medicine lens, dyslipidemia is rarely a primary condition but is frequently a downstream effect of broader metabolic dysfunction, chronic inflammation, oxidative stress, and gut dysbiosis. This perspective goes beyond conventional cholesterol-centric models, recognizing dyslipidemia as a marker of complex physiological disruptions [7,8,9,10].

Metabolic Dysfunction and Insulin Resistance

  • Dyslipidemia often results from insulin resistance, where impaired cellular response to insulin leads to increased free fatty acid release from adipose tissue, altered hepatic lipid metabolism, and overproduction of VLDL particles [11,12].
  • This pattern is typical in metabolic syndrome and type 2 diabetes contributing to high triglycerides, low HDL, and an excess of small, dense, LDL particles, all of which are highly atherogenic [12,13].

Chronic Inflammation and Oxidative Stress

  • Chronic, low grade inflammation is commonly observed in individuals with dyslipidemia and metabolic syndrome. Inflammatory cytokines disrupt lipid transport, exacerbate endothelial dysfunction, and promote atherogenesis [7,8].
  • Oxidative stress, the imbalance between reactive oxygen species (ROS) and antioxidant defenses, amplifies lipid peroxidation and vascular injury. ROS can oxidize LDL particles, promoting foam cell formation and atherosclerotic plaque development [8,14].

Gut Dysbiosis

  • Gut microbiota imbalance – or dysbiosis- dysregulates intestinal barrier integrity, increasing permeability and allowing lipopolysaccharides and other toxins to enter systemic circulation. This process triggers further inflammation, hepatic lipid synthesis, and oxidative stress, thereby contributing to dyslipidemia [7,8,14].
  • Gut-derived metabolites and short-chain fatty acids modulate pathways linked to both inflammation and lipid metabolism, reinforcing the gut-liver-metabolism axis [14].

Secondary Causes and Contributing Disorders

Dyslipidemia is most commonly secondary to other medical or lifestyle-related disorders rather than being purely genetic [5,11,13]:

  • Insulin resistance/ metabolic syndrome: Strongly linked to high triglycerides, low HDL, and abnormal LDL particle distribution [11,12,13].
  • Chronic stress and cortisol excess: Chronic stress elevates cortisol, which promotes visceral adiposity, hepatic steatosis, and dysregulated lipogenesis, exacerbating abnormal lipid profiles [9].
  • Hypothyroidism: Low thyroid hormone reduces LDL clearance and raises cholesterol levels, particularly LDL. Dyslipidemia is a recognized complication of untreated hypothyroidism [11,13].
  • Non-alcoholic fatty liver disease (NAFLD): Hepatic steatosis impairs VLDL secretion and cholesterol metabolism, closely linking NAFLD with dyslipidemia [14].
  • Poor sleep: Insufficient or disordered sleep is associated with worsened insulin resistance, increased inflammation and disruption of circadian regulation on lipid metabolism, indirectly promoting dyslipidemia [9].
Root CauseHow it Promotes Dyslipidemia
Insulin resistanceAlters FFA flux and VLDL secretion, raising triglycerides, small dense LDL
Chronic inflammationDisrupts lipid metabolism, promotes endothelial dysfunction
Oxidative stressOxidizes LDL, damages vasculature, increases plaque risk
Gut dysbiosisIncreases permeability, triggers inflammation, affects lipid absorption
Stress and cortisol excessRaises hepatic lipogenesis, steatosis, VLDL overproduction
HypothyroidismReduces hepatic LDL clearance, raises LDL cholesterol
NAFLD (hepatic steatosis)Perturbs VLDL secretion and fat metabolism
Poor sleepIncreases insulin resistance and inflammation
Table 1. Summary Table for Key Functional Root Causes and Connections

From a functional medicine perspective, dyslipidemia reflects deeper systemic imbalances, rarely existing as a true primary disorder. Addressing its root causes especially insulin resistance, inflammation, oxidative stress, and gut health offers a systems level framework for effective intervention, rather than simply managing lipid levels in isolation [5,9,11,13,14].

Key Biomarkers Beyond Basic Lipid Panel

Modern cardiovascular risk assessment goes far beyond total cholesterol and LDL-C, integrating advanced biomarkers that offer more precise and actionable insights. Here’s an expert summary of the most relevant test, their significance, and functional medicine implications [15,16,17]

BiomarkersTest TypeWhy It MattersFunctional Insight
ApoBBloodDirect count of all atherogenic particle number [15,17]Superior predictor of CVD risk vs LDL-C; guides therapy [15,16]
LDL-P (Particle size/number)NMR/Advanced lipidMeasures total LDL particle number & small dense LDL [15,18]Small dense LDL more atherogenic; clarifies risk when LDL-C looks “normal” [15,18]
TG-HDL RatioBloodMarkers of insulin resistance/ metabolic syndrome [19]Ratio <2 (mmol/L) or <0.5-1.9 (mg/dL) is ideal; higher= increased cardiometabolic risk [19]
hsCRP (high-sensitivity C-reactive protein)BloodSensitive inflammatory biomarker [4,19]Marker of vascular inflammation and residual risk; may guide intervention intensity [4,16]
Fasting insulin/ HOMA-IRBlood/CalculationAssesses insulin sensitivity/ resistance [7,19]Target fasting insulin <5μIU/mL ; elevated= higher CVD/metabolic risk [7]
Lp(a) (Lipoprotein(a))BloodGenetic risk; pro-atherogenic particle [7,20]Stable across life; hard to modify, but higher= substantial CVD risk [20]
Oxidized LDLSpecialized BloodIndicator of oxidative burden and atherogenesis [20,21]Increases plaque instability: managing oxidative stress and inflammation is key [20,21]
Table 2. Advanced Biomarkers: Test, Rationale & Importance

Explanation of Why These Biomarkers Matter

  • ApoB reflects the total number of atherogenic lipoproteins, not just cholesterol carried by them- providing a more direct measure of “dangerous” particles that can infiltrate artery walls. It outperforms LDL-C for predicting heart attack and stroke risk, especially if LDL-C is near target but metabolic syndrome is present [15,16].
  • LDL Particle Number/ Size (LDL-P, sdLDL): Individual with many small, dense LDL particles face more risk, as these particles are more likely to penetrate the endothelium and undergo oxidative modification. Their measurement supersedes basic LDL-C, especially for identifying high-risk phenotypes [15,18].
  • TG-HDL Ratio is a reliable surrogate for insulin resistance, with a ratio <2 (mg/dL units: 0.5-1.9) considered ideal. Elevated TG and low HDL together suggest a pro-atherogenic, insulin-resistant state [19].
  • hsCRP picks up subtle systemic inflammation, a key driver of atherosclerosis; elevated levels warrant more aggressive risk management [4,16,19].
  • Fasting Insulin /HOMA-IR uncovers chronic hyperinsulinemia- which often precedes overt dyslipidemia and is foundational in metabolic disease. Target fasting insulin <5μIU/mL is optimal [7].
  • Lp(a) quantifies genetically determined lipid particles that directly accelerate atherogenesis. Although Lp(a) is resistant to modification, lowering inflammation and oxidative stress through lifestyle may still help mitigate risk [7,20].
  • Oxidized LDL quantifies the LDL particles altered by oxidative stress, which are uniquely atherogenic and destabilize plaques. Managing oxidative burden with antioxidants and anti-inflammatory interventions becomes a more targeted approach in those with high oxidized LDL [20,21].

Functional Insight: Clinical Value Beyond LDL-C

  • ApoB, particle number and Lp(a) can predict cardiovascular events better than basic LDL-C and help tailor treatment intensity [15,16,17].
  • Small dense LDL and High TG-HDL ratios signify more aggressive metabolic dysfunction and advocate for a more holistic intervention [15,19].
  • hsCRP and oxidized LDL mark inflammatory and oxidative stress that fuels, plaque formation, guiding practitioners to address these drivers, not just cholesterol [4,20,21].
  • Fasting insulin and HOMA-IR identify those with preclinical or “silent” insulin resistance- often missed by the basic panel [7,19].
  • White Lp(a) is not easily modified, understanding risk encourages proactive interventions targeting lifestyle and inflammation [7,20].
  • Addressing oxidative burden and chronic inflammation- visible in oxidized LDL and hsCRP-enables a root cause, functional medicine approach [20,21].

These insights and recommendations stem from robust clinical studies, guideline panels, and functional medicine perspectives that increasingly advocate for broader CVD risk assessment beyond traditional cholesterol testing [15,16,17,18,19,20,21].

Root Causes To Investigate in Dyslipidemia

Detailed investigation into dyslipidemia from a functional medicine perspective reveals multiple interconnected root causes. These extend beyond genetics and conventional risk factors, embracing diet, lifestyle, toxin exposure, endocrine function, and gut health [22,23,24].

Dietary Factors

  • High Intake of Refined Carbohydrates and Processed Foods: Diets rich in simple sugars and highly processed ingredients promote insulin resistance, inflammation, and gut microbiota imbalance, leading to abnormal lipid profiles, especially high triglycerides and small dense LDL [24].
  • Excess Saturated/ Trans Fats: Consumption of unhealthy fats drives hepatic lipid synthesis and modifies lipid particle size and density, raising cardiovascular risk [24].
  • Deficiency in Fiber and Health Fats: Low fiber intake affects lipid metabolism, gut barrier integrity, and microbial diversity, while insufficient omega-3 fatty acids reduce anti-inflammatory capacity and impair lipid regulation [24].

Lifestyle Factors

  • Physical Inactivity: Sedentary behavior decreases insulin sensitivity and increases adiposity, fueling dyslipidemia and metabolic syndrome development [24].
  • Poor Sleep and Circadian Disruption: Lack of restorative sleep elevates stress hormone production (cortisol), impairs insulin function, and alters lipid homeostasis [24].
  • Chronic Stress: Chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis results in cortisol excess, which increases visceral fat deposition, impairs thyroid function, and elevates lipid synthesis in the liver [24].

Environmental Toxins

  • Exposure to Endocrine-Disrupting Chemicals (EDCs): Toxins such as BPA, pesticides, heavy metals, and “obesogens” disrupt hormonal regulation of metabolism and directly damage cellular lipid processing [22,24,25].
  • Dietary and Microbial Toxins: Environmental chemicals and toxic metabolites, such as those produced by altered gut microbiota, impair lipid homeostasis and induce inflammation [22,23,24].

Endocrine Factors

  • Thyroid Dysfunction: Hypothyroidism reduces LDL receptor activity and lowers the rate of LDL clearance, leading to elevated cholesterol [24].
  • Adrenal Dysregulation (Chronic Stress Cortisol): Persistent cortisol excess is linked to insulin resistance and abnormal hepatic lipid production, worsening dyslipidemic patterns [24].
  • Impairment of Satiety Hormones (Leptin, Ghrelin): Dysfunctional leptin and ghrelin signaling promotes overeating, altered energy balance, and metabolic dysregulation [24].

Gut Health

  • Microbiome Dysbiosis: Disrupted gut microbial diversity affects short-chain fatty acid (SCFA) production, increases gut permeability (“leaky gut”), and allow endotoxins (LPS) to activate pro-inflammatory pathways, aggravating insulin resistance and lipid abnormalities [23,26,27].
  • Toxic Load and Gut-Liver Axis: Toxins crossing an impaired gut barrier increase hepatic inflammation and lipid dysregulation [23,26,27].

Functional Medicine Approach: Why Root Cause Investigation Matters

  • Root-cause assessment informs targeted interventions: Correcting diet, improving sleep, reducing toxin exposure, optimizing hormones, and restoring gut balance are essential to effective management, not just symptomatic control [22,23,24].
  • Diet and lifestyle modification: Intervention in diet and lifestyle is foundational, while detoxification protocols and environmental risk mitigations target toxin-induced dyslipidemia [22,24].
  • Comprehensive hormone assessment: evaluating the thyroid, adrenal, and satiety hormone axes allows for tailored endocrine optimization [24].
  • Gut-directed therapies: Restoring microbiome diversity through diet, probiotics, and prebiotics can promote metabolic and lipid, health, while addressing leaky gut reduces inflammatory triggers [23,26,27].

Functional Medicine Interventions

Functional medicine leverages comprehensive strategies- nutrition, lifestyle, and supplements– for deep rooted and sustainable dyslipidemia management. These interventions target metabolic, inflammatory, and oxidative pathways [10,28,29].

Nutrition Interventions

  • Emphasis on Anti-Inflammatory Diets: Dietary interventions prioritize anti-inflammatory nutrient patterns, such as the Mediterranean diet (rich in vegetables, fruits, whole grains, legumes, nuts, seeds, and olive oil). These diets decrease LDL, triglycerides, and inflammation [10,30,31].
  • Replace Saturated/ Trans Fats: Shift from saturated/trans fats in processed foods to monounsaturated (MUFA) and polyunsaturated fats (PUFA) from avocado, olive oil, nuts, and fatty fish. This change lowers LDL-C, improves HDL, and reduces atherogenic particle size [31,32].
  • Increase Fiber Intake: High-fiber foods (leafy greens, legumes, berries, chia/flax seeds, oats) help reduce cholesterol absorption and regulate blood sugar [10,29].
  • Reduce Refined Carbohydrates: Limiting simple sugars and highly processed carbs supports triglyceride reduction and normalizes HDL [30,31,32].
  • Omega-3 Rich Foods: Fatty fish (salmon, sardines), walnuts, and flaxseeds deliver omega-3s that attenuate triglyceride levels and systemic inflammation [10,29,31].

Lifestyle Interventions

  • Regular Exercise: Aerobic activity (150+ minutes/week) and resistance training improve the lipid profile, insulin sensitivity, and systemic inflammation. Exercise also increases HDL and help shifts the LDL particle profile toward larger, less atherogenic particles [5,10,32].
  • Weight Management: Sustainable weight reduction, especially if overweight/obese, decreases triglycerides and raises HDL. Even modest weight loss has significant metabolic benefits [10].
  • Better Sleep & Stress Management: Adequate restorative sleep and stress-reducing practices such as mindfulness and meditation reduce cortisol and support cholesterol regulation [10,32].
  • Limit Alcohol & Avoid Tobacco: Both tobacco and excessive alcohol intake worsen dyslipidemia through inflammatory and oxidative effects; reducing or eliminating use can improve lipid and cardiovascular health [10].

Supplement Interventions

  • Omega-3 Fatty Acids: Fish oil supplements (EPA/DHA) lower triglyceride levels and have anti-inflammatory benefits [29,33].
  • Red Yeast Rice (RYR): Contains monacolin K, which inhibits cholesterol synthesis (like statins). Studies show reductions in total cholesterol and LDL-C, batches must be citrinin-free for safety [29,33].
  • Berberine: Improves lipid metabolism, lowers cholesterol, triglycerides, and glucose, and has demonstrated efficacy in clinical trials [29,33].
  • Niacin: Can raise HDL and lower triglycerides; use cautiously as it may affect glucose and uric acid levels [29,33].
  • Policosanol & Plant Sterols: These natural substances can modesty reduce LDL-C when incorporated into diet or supplement routines [33].
  • CoQ10, Lipoic Acid, Garlic: These antioxidants and botanicals support lipid management by reducing oxidative burden, normalizing cholesterol levels, and protecting vascular health [10,29].
  • Fiber Supplements (e.g., psyllium husk): Further assist cholesterol lowering and digestive health [29,33].

Functional Medicine Insights

  • Personalized Intervention: Approaches are tailored by phenotype, biomarkers and underlying root causes- enabling more durable outcomes than generic LDL-C lowering alone [10,29,33].
  • Synergistic Effects: Combining nutrition, lifestyle, and evidence-based supplements can produce additive or synergistic lipid-lowering benefits, especially in those intolerant or resistant to medications [29,33].
  • Clinical Monitoring: Tracking advanced lipid biomarkers, inflammatory markers, and glycemic metrics guides therapeutic adjustments and intervention intensity [33].

Clinical Triggers For Urgent Action in Dyslipidemia

Certain biomarker thresholds in dyslipidemia signal the need for immediate or intensified clinical intervention due to sharply increased risk for acute or long term complication. Here are the key clinical triggers and their benchmarks:

  1. Triglycerides >500mg/dL: Acute Pancreatitis Risk
    • Risk: Fasting triglyceride (TG) levels above 500 mg/dL place the patient in a danger zone for developing acute pancreatitis, especially as levels near or exceed 1,000mg/dL. Pancreatitis at these levels can develop rapidly and may be life-threatening, requiring urgent care [34,35,36].
    • Actions: Immediate intervention is recommended to rapidly lower TG levels. Management typically includes very low-fat diets, medication, treatment of secondary factors (e.g., diabetes control), and sometimes hospitalization if pancreatitis symptoms arise [34,36].
    • Why It Matters: Pancreatic lipase breaks down excessive triglycerides, releasing free fatty acids that are toxic to pancreatic tissue causing an inflammatory cascade and leading to cell death and severe inflammation [34,35].
  2. Very High Lipoprotein(a) [Lp(a)]
    • Risk: Lp(a) levels above 50mg/dL (≈ 125 nmol/L) are high risk; values above 180 mg/dL (>430nmol/L or >99th percentile) are associated with an extremely high lifelong risk of atherosclerotic cardiovascular disease (ASCVD), even in the absence of other classic risk factors [37,38].
    • Actions : While Lp(a) is largely genetically determined and resistant to current medical therapy, recognition of extremely elevated Lp(a) should prompt very intensive management of all other modifiable cardiovascular risk factors and consideration of emerging therapies in clinical trials [37].
    • Why It Matters: Very high Lp(a) is a potent, independent driver of accelerated atherosclerosis, early myocardial infarction, stroke, and progression of peripheral artery disease [37,38].
  3. Apolipoprotein B (ApoB) >120 mg/dL
    • Risk: ApoB reflects the total number of atherogenic lipoprotein particles. An ApoB above 120mg/dL is linked to markedly increased risk of cardiovascular events, regardless of LDL-C levels [39].
    • Action: Such a finding should prompt aggressive lipid lowering (lifestyle, statins, or non-statin agents), and stricter control of other vascular risk factors (blood pressure glycemic control, etc.) [39].
    • Why It Matters: ApoB is a superior predictor of ASCVD risk to LDL-C. Each plaque-forming particle has a single ApoB, so its count directly quantifies atherogenic burden. Action is justifies at levels well below 120, but >120 mg/dL represents a threshold of particularly elevated risk [39].
Biomarker/ ThresholdClinical TriggerUrgency & ActionWhy It Matters
Triglycerides >500mg/dLHigh risk of acute pancreatitisImmediate lowering, urgent carePancreatitis can be life-threatening [34,35,36]
Lp(a) >180mg/dL (>99th pct)Extremely high, persistent ASCVD riskIntensify all CVD risk reductionMajor genetic driver of early, aggressive CVD [37,38]
ApoB >120mg/dLDirect measure of elevated atherogenic particlesAggressive lipid/lifestyle RxBest surrogate for total plaque-promoting particles[39]
Table 3. Reference Table

Comprehensive Clinical Action Plan for Dyslipidemia

Managing dyslipidemia effectively involves a multisystem approach- starting from advanced diagnostics, root cause identification, individualized nutrition and supplement plans, consistent biomarker tracking, and foundational lifestyle medicine [5,7,40,41].

  1. Assess Full Lipid, Metabolic, and Inflammatory Panels
    • Panel Components:
      • Advanced lipid biomarkers (ApoB, LDL-P/particle size, Lp(a), TG-HDL ratio)
      • Insulin sensitivity markers (fasting insulin, HOMA-IR)
      • Thyroid function (TSH, fT4, fT3)
      • Inflammatory markers (hs-CRP, ferritin)
      • Liver and renal function panels
    • Rationale:
      • Enables assessment of total atherogenic particle burden, insulin resistance, systemic inflammation, and secondary metabolic/ endocrine contributors [7,42,43].
  2. Identify Root Causes
    • Systematic Evaluation:
      • Insulin resistance (high TG, low HDL, elevated fasting insulin, high HOMA-IR) [41].
      • Thyroid dysfunction [5,43].
      • Chronic stress or corticosteroid excess
      • Gut health (dysbiosis, elevated inflammatory markers) [7].
      • Environmental toxins (heavy metals, bisphenol exposures) [7].
    • Rationale :
      • Treatment success and durability depend on addressing underlying metabolic, endocrine, and environmental drivers [7,44].
  3. Tailor Nutrition Interventions
    • Dietary Principles:
      • Focus on low glycemic foods to reduce insulin demand (vegetables, berries, legumes, whole grains) [40].
      • Adopt anti-inflammatory dietary patterns (Mediterranean diet, high in extra virgin olive oil, nuts, fatty fish, greens) [32,40].
      • Elevate fiber, phytonutrients, and omega-3 intake; minimize processed foods, saturated/trans fats, and refined carbs [32,40].
    • Individualization:
      • Registered dietitian guidance and education for sustainable dietary change and adaptation based on lab data and patient preferences [40].
  4. Add Targeted Supplements
    • Evidence-Based Choices:
      • Omega-3 fatty acids for triglyceride and inflammation reduction
      • Berberine, red yeast rice, niacin, plant sterols/fiber for specific lipid abnormalities [28,29].
      • Probiotics and antioxidants to support gut health and oxidative stress management [7].
    • Clinical Monitoring:
      • Individual supplement plans based on biomarker response and tolerance; avoid over-supplementation or unproven remedies [28].
  5. Track Biomarkers Every 3-6 Months
    • Serial Monitoring:
      • Repeat advanced lipid, metabolic, and inflammatory panels every three to six months [7,41].
    • Outcome Focus:
      • Monitor changes to guide therapy intensity and maintain engagement with the care plan [42,43].
  6. Make Lifestyle Medicine the Foundation
    • Assemble Core Interventions:
      • Regular physical activity at recommended levels [5,32].
      • Stress management (mindfulness, sleep hygiene, relaxation techniques)
      • Address behavioral and psychosocial support for habit formation [7,40].
    • Rationale:
      • Lifestyle changes form the bedrock of durable risk reduction across diverse dyslipidemia phenotypes [7,32,40].

Conclusion

Dyslipidemia is a multifactorial metabolic disorder that demands a nuanced approach extending beyond traditional cholesterol-focused assessment. This article highlights the importance of recognizing dyslipidemia as a marker of deeper systemic dysfunction, often secondary to insulin resistance, chronic inflammation, oxidative stress, endocrine disturbance, poor sleep, and gut dysbiosis.

Modern management requires a shift to advanced biomarker analysis- such as ApoB, LDL particle size, TG-HDL ratio, hsCRP, and Lp(a)- to accurately assess cardiovascular risk and guide individualized interventions, Root cause identification, including evaluation of diet, lifestyle, environmental toxins, endocrine status, and gut health, enables more targeted and effective therapeutic strategies.

Functional medicine intervention focus on low glycemic, anti-inflammatory nutrition, regular physical activity, restorative sleep, stress management, and judicious use of supplements, all tailored to the patient’s phenotype and underlying drivers. Clinical vigilance in identifying urgent triggers, such as dangerously elevated triglycerides or atherogenic particles, ensures timely and intensive action when needed.

Ultimately, sustainable success in treating dyslipidemia arises from a holistic and proactive clinical action plan-one that prioritizes personalized root cause resolution, ongoing biomarker tracking, and foundational lifestyle medicine. By embracing this comprehensive model, clinicians and patients can advance prevention, optimize cardiometabolic health, and achieve durable improvement in outcomes.

References

  1. Clerc A, Togni M, Cook S. Call for a consensual definition of dyslipidemia in coronary angiography trials. Frontiers in Cardiovascular Medicine. 2025 Feb 5;12.
  2. Dyslipidemia – an overview | ScienceDirect Topics [Internet]. www.sciencedirect.com. Available from: https://www.sciencedirect.com/topics/neuroscience/dyslipidemia
  3. Reyhana Yahya Dyslipidemia beyond LDL Dyslipidemie, meer dan alleen LDL [Internet]. [cited 2025 Aug 23]. Available from: https://repub.eur.nl/pub/115407/Reyhana-Yahya-thesis_embargo_version_PDF.pdf
  4. Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. The Journal of Clinical Investigation [Internet]. 2022 Jan 4 [cited 2022 Dec 12];132(1):e148559. Available from: https://pubmed.ncbi.nlm.nih.gov/34981790/
  5. Pappan N, Rehman A, Awosika AO. Dyslipidemia [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560891/
  6. Cabau L. Beyond LDL: A Comprehensive Approach to Cardiovascular Health [Internet]. Biosfer Teslab. 2025 [cited 2025 Aug 26]. Available from: https://biosferteslab.com/beyond-ldl/
  7. Cloyd J. Functional medicine high cholesterol protocol [Internet]. Rupa Health. 2023. Available from: https://www.rupahealth.com/post/functional-medicine-high-cholesterol-protocol
  8. Hamid Mostafavi Abdolmaleky, Zhou JR. Gut Microbiota Dysbiosis, Oxidative Stress, Inflammation, and Epigenetic Alterations in Metabolic Diseases. Antioxidants [Internet]. 2024 Aug 14;13(8):985–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351922/
  9. Murray S. Beyond Statins: Exploring Functional Medicine Approaches to DyslipidemiaSteve Murray February 9, 2025 Health [Internet]. Health Architects SA. 2025 [cited 2025 Aug 26]. Available from: https://www.healtharchitectssa.com/post/beyond-statins-exploring-functional-medicine-approaches-to-dyslipidemia
  10. Dyslipidemia – Functional Wellness Clinic and Consultation [Internet]. Functional Wellness Clinic and Consultation. 2024 [cited 2025 Aug 26]. Available from: https://functionalwellnesscc.com/dyslipidemia/
  11. What Are Secondary Causes of Dyslipidemia? [Internet]. Doctronic. 2023 [cited 2025 Aug 26]. Available from: https://www.doctronic.ai/conditions-diseases/what-are-secondary-causes-of-dyslipidemia-qcaMRY/
  12. Ginsberg HN. Insulin resistance and cardiovascular disease. Journal of Clinical Investigation. 2000 Aug 15;106(4):453–8.
  13. ANNE. Dyslipidemia [Internet]. MSD Manual Professional Edition. MSD Manuals; 2018. Available from: https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia
  14. Zhou M, Lv J, Chen X, Shi Y, Chao G, Zhang S. From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease. Annals of Hepatology. 2025 Jan;30(1):101777.
  15. Pourfarzib R, Morris P, McLain K, Malave H, Underberg J, Le N-Anh, et al. Relationship between plasma apolipoprotein B concentrations and LDL particle number. Research Reports in Clinical Cardiology [Internet]. 2014 Sep;237. Available from: https://www.dovepress.com/relationship-between-plasma-apolipoprotein-b-concentrations-and-ldl-pa-peer-reviewed-fulltext-article-RRCC
  16. German CA, Shapiro MD. Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science [Internet]. Radcliffe Cardiology. European Cardiology Review; 2020 [cited 2025 Aug 26]. Available from: https://www.ecrjournal.com/articles/assessing-atherosclerotic-cardiovascular-disease-risk-advanced-lipid-testing-state-science?language_content_entity=en
  17. Daglis S. Emerging Biomarkers for Lipid Disorders: Beyond Traditional Lipid Profiles [Internet]. Rupa Health. 2024. Available from: https://www.rupahealth.com/post/emerging-biomarkers-for-lipid-disorders-beyond-traditional-lipid-profiles
  18. Xiao L, Zhang K, Wang F, Wang M, Huang Q, Wei C, et al. The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population. Lipids in Health and Disease. 2023 Jul 21;22(1).
  19. Rizal Fahly, Adam FMS, Haerani Rasyid, Aman AM, Bakri S, Idar Mappangara, et al. Relationship between TG/HDL-C Ratio and TyG Index with Chronic Inflammation in People with Prediabetes: A Cross-Sectional Study. Clinical Diabetology. 2022 Oct 31;11(5):321–5.
  20. Gilliland TC, Liu Y, Reza Mohebi, Miksenas H, Haidermota S, Wong M, et al. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. Journal of the American College of Cardiology. 2023 May 1;81(18):1780–92.
  21. Yang HS. Lipid Biomarkers and Cardiometabolic Diseases: Critical Knowledge Gaps and Future Research Directions. Metabolites. 2025 Feb 7;15(2):108.
  22. What is the evidence-based impact of functional medicine on hyperlipidemia, considering factors such as diagnostic testing, gut microbiome, stress, inflammation, immune dysregulation, sleep disturbances, and toxin exposure? [Internet]. Droracle.ai. 2025 [cited 2025 Aug 26]. Available from: https://www.droracle.ai/articles/31158/evidence-based-medicine-on-functional-medicine-impact-on-hyperlipidemia-with-focus-on-testing-gut-microbiome-stress-inflammation-immune-deregulation-sleep-and-toxins
  23. Rahman MdM, Islam F, Or-Rashid MdH, Mamun AA, Rahaman MdS, Islam MdM, et al. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation. Frontiers in Cellular and Infection Microbiology. 2022 Jun 20;12.
  24. Refining “Dysbiosis”: Using Big-Data Analysis and Novel Interventions [Internet]. Personalized Lifestyle Medicine Institute. 2024. Available from: https://plminstitute.org/plmi-blog/the-connection-between-endocrine-function-metabolic-disorders-obesity/
  25. Chi Y, Zhu L, Wang Y, Peng C, Lin Y, Ji S, et al. Long-term Bisphenol S exposure induced gut microbiota dysbiosis, obesity, hepatic lipid accumulation, intestinal lesions and dyslipidemia in mice. Toxicology. 2024 Apr 6;504:153798–8.
  26. The Link Between Your Gut Health and Cholesterol [Internet]. Vibrant-wellness.com. Vibrant Wellness; 2019 [cited 2025 Aug 26]. Available from: https://vibrant-wellness.com/blog/the-link-between-your-gut-health-and-cholesterol
  27. You M, Zhou L, Wu F, Zhang L, Zhu S, Zhang H. Probiotics for the treatment of hyperlipidemia: Focus on gut-liver axis and lipid metabolism. Pharmacological Research [Internet]. 2025 Mar 10;214:107694. Available from: https://www.sciencedirect.com/science/article/pii/S1043661825001197
  28. Cicero AFG, Fogacci F, Stoian AP, Vrablik M, Al Rasadi K, Banach M, et al. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? Current Atherosclerosis Reports. 2021 Aug 4;23(10).
  29. Emily Gutierrez E, Taylor Hohmann T. Dietary Supplements in Dyslipidemia. OBM Integrative and Complementary Medicine. 2018 May 24;3(2):1–1.
  30. Kirkpatrick CF, Sikand G, Petersen KS, Cheryl A.M. Anderson, Aspry KE, Bolick JP, et al. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. Journal of Clinical Lipidology. 2023 Jun 1;17(4).
  31. Chopra A. Dietary management of dyslipidemia. Indian Heart Journal. 2023 Dec 1;76(1).
  32. Enkhmaa B, Surampudi P, Anuurad E, Berglund L. Lifestyle Changes: Effect of Diet, Exercise, Functional Food, and Obesity Treatment on Lipids and Lipoproteins [Internet]. Nih.gov. MDText.com, Inc.; 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326737/
  33. Cicero AFG, Fogacci F, Stoian AP, Vrablik M, Al Rasadi K, Banach M, et al. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? Current Atherosclerosis Reports. 2021 Aug 4;23(10).
  34. Acute Pancreatitis Risk | Lower Triglycerides [Internet]. Lower Triglycerides. 2025 [cited 2025 Aug 26]. Available from: https://lowertriglycerides.com/acute-pancreatitis-risk/
  35. For Patients With High Triglycerides (TGs) | Lower Triglycerides [Internet]. Lower Triglycerides. 2025 [cited 2025 Aug 26]. Available from: https://lowertriglycerides.com/patient/
  36. Smith LA, Stanley AJ, Bergman JJ, Ralf Kiesslich, Hoffman A, Tjwa ET, et al. Hemospray Application in Nonvariceal Upper Gastrointestinal Bleeding. Journal of Clinical Gastroenterology [Internet]. 2013 Dec 11 [cited 2025 Aug 26];48(10):e89–92. Available from: https://siphoxhealth.com/articles/can-very-high-triglycerides-cause-pancreatitis
  37. Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): Actionable strategies for risk assessment and mitigation. American Journal of Preventive Cardiology [Internet]. 2024 Jun 1;18:100651. Available from: https://pubmed.ncbi.nlm.nih.gov/38646021/
  38. Nurmohamed NS, Moriarty PM, Stroes ES. Considerations for routinely testing for high lipoprotein(a). Current Opinion in Lipidology. 2022 Oct 18;34(4):174–9.
  39. Dyslipidemia in Adults [Internet]. Elsevier.health. 2025 [cited 2025 Aug 26]. Available from: https://elsevier.health/en-US/preview/dyslipidemia-in-adults
  40. Williams L, Baker-Smith CM, Bolick J, Carter J, Kirkpatrick C, Ley SL, et al. Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective. Journal of Clinical Lipidology [Internet]. 2022 Jul 30; Available from: https://www.sciencedirect.com/science/article/pii/S1933287422002185
  41. National Lipid Association. Practical Pearls: Dyslipidemia Management in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | National Lipid Association Online [Internet]. Lipid.org. 2024. Available from: https://www.lipid.org/lipid-spin/spring-2024/practical-pearls-dyslipidemia-management-metabolic-dysfunction-associated
  42. Yoon J, Han T, Heo SJ, Kwon YJ. Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study. Journal of Clinical Lipidology [Internet]. 2024 Jan 10;18(2):e251–60. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1933287424000011
  43. Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocrine Reviews [Internet]. 2021 Oct 22;43(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277652/
  44. Pace Hospitals. Dyslipidemia – Symptoms, Causes, Diagnosis and Treatment [Internet]. Pacehospital.com. 2024. Available from: https://www.pacehospital.com/dyslipidemia-symptoms-causes-risk-factors-diagnosis-and-treatment